Dr. Locke J. Bryan
Claim this profileAugusta University Medical Center
Studies Lymphoma
Studies Non-Hodgkin's Lymphoma
8 reported clinical trials
19 drugs studied
Area of expertise
1Lymphoma
Stage IV
Stage III
Stage I
2Non-Hodgkin's Lymphoma
MYC positive
BCL2 positive
BCL6 positive
Affiliated Hospitals
Clinical Trials Locke J. Bryan is currently running
Oral Azacitidine + R-miniCHOP
for Diffuse Large B-Cell Lymphoma
This phase II/III trial compares the side effects and activity of oral azacitidine in combination with the standard drug therapy (reduced dose rituximab-cyclophosphamide, doxorubicin, vincristine, and prednisone \[R-miniCHOP\]) versus R-miniCHOP alone in treating patients 75 years or older with newly diagnosed diffuse large B cell lymphoma. R-miniCHOP includes a monoclonal antibody (a type of protein), called rituximab, which attaches to the lymphoma cells and may help the immune system kill these cells. R-miniCHOP also includes prednisone which is an anti-inflammatory medication and a combination of 3 chemotherapy drugs, cyclophosphamide, doxorubicin, and vincristine. These 3 chemotherapy drugs, as well as oral azacitidine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Combining oral azacitidine with R-miniCHOP may shrink the cancer or extend the time without disease symptoms coming back or extend patient's survival when compared to R-miniCHOP alone.
Recruiting1 award Phase 2 & 314 criteria
IMPT-314
for Non-Hodgkin's Lymphoma
This is a Phase 1/2, multi-center, open-label study evaluating the safety and efficacy of IMPT-314, a bispecific chimeric antigen receptor (CAR) targeting cluster of differentiation (CD)19 and CD20 in participants with aggressive B-cell NHL. Three cohorts of participants will be enrolled: 1) CAR T naïve after at least two or more prior lines of treatment, 2) CAR T experienced and 3) refractory disease or relapse within one year of first line therapy. Up to approximately 90 patients (30 per cohort) will be enrolled in dose finding Phase 1 part of the study, which will determine the recommended phase 2 dose. Phase 2 will enroll up to approximately 60 additional participants (20 per cohort) to evaluate further the safety and efficacy of IMPT-314. IMPT-314 treatment consists of a single infusion of CAR-transduced autologous T cells administered intravenously after a conditioning chemotherapy regimen consisting of fludarabine and cyclophosphamide, administered over 3 days. Individual participants will remain in the active post-treatment period for approximately 2 years. Participants will continue in long-term follow-up for 15 years from treatment.
Recruiting1 award Phase 1 & 2
More about Locke J. Bryan
Clinical Trial Related5 years of experience running clinical trials · Led 8 trials as a Principal Investigator · 5 Active Clinical TrialsTreatments Locke J. Bryan has experience with
- Ibrutinib
- Rituximab
- Autologous Hematopoietic Stem Cell Transplantation
- IMPT-314
- Venetoclax
- Obinutuzumab
Breakdown of trials Locke J. Bryan has run
Lymphoma
Non-Hodgkin's Lymphoma
B-Cell Lymphoma
Hodgkin's Lymphoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Locke J. Bryan specialize in?
Locke J. Bryan focuses on Lymphoma and Non-Hodgkin's Lymphoma. In particular, much of their work with Lymphoma has involved Stage IV patients, or patients who are Stage III.
Is Locke J. Bryan currently recruiting for clinical trials?
Yes, Locke J. Bryan is currently recruiting for 5 clinical trials in Augusta Georgia. If you're interested in participating, you should apply.
Are there any treatments that Locke J. Bryan has studied deeply?
Yes, Locke J. Bryan has studied treatments such as Ibrutinib, Rituximab, Autologous Hematopoietic Stem Cell Transplantation.
What is the best way to schedule an appointment with Locke J. Bryan?
Apply for one of the trials that Locke J. Bryan is conducting.
What is the office address of Locke J. Bryan?
The office of Locke J. Bryan is located at: Augusta University Medical Center, Augusta, Georgia 30912 United States. This is the address for their practice at the Augusta University Medical Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.